BRD4-degrader-AT1-DataSheet-MedChemExpress
HSF1A_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Diva Decloaker 10X Pretreatment Reagent 说明书
Intended Use:For In Vitro Diagnostic UseHeat induced antigen retrieval of formalin-fixed paraffin-embedded (FFPE) tissues for immunohistochemistry (IHC) procedures. The clinical interpretation of any staining or its absence should be complimented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.Summary & Explanation:Diva Decloaker is a heat retrieval solution that is compatible with virtually all antibodies and eliminates the need for multiple buffers including citrate buffer, EDTA or high pH tris buffers. Antibody titers are doubled and tripled when compared to citrate buffer, pH 6.0. Diva Decloaker incorporates Assure™ tech nology, a color-coded high temperatures pH indicator solution. The end-user is assured by visual inspection that the solution is at the correct dilution and pH. This product is specially formulated for superior pH stability at high temperatures and will help prevent the possibility of losing pH sensitive antigens. Diva Decloaker is non-toxic, non-flammable, odorless and sodium azide and thimerosal free.Known Applications:Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As:100mlDiva Decloaker, 10X concentrate (DV2004LX)500mlDiva Decloaker, 10X concentrate (DV2004MX)Materials and Reagents (Needed But Not Provided): Microscope slides, positively chargedDesert Chamber* (Drying oven)Positive and negative tissue controlsXylene (Could be substituted with xylene substitute*)Ethanol or reagent alcoholDecloaking Chamber* (Pressure cooker)Deionized or distilled waterWash buffer*(TBS/PBS)Enzyme digestion*Avidin-Biotin Blocking Kit*(Labeled Streptavidin Kits Only) Peroxidase block*Protein block*Primary antibody*Negative control reagents*Detection kits*Detection components*Chromogens*Hematoxylin*Bluing reagent*Mounting medium** Biocare Medical Products: Refer to a Biocare Medical catalog for further information regarding catalog number and ordering information. Certain reagents listed above are based on specific application and detection system used. Storage and Stability:Store at room temperature. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at room temperature.Protocol Recommendations:1. Deparaffinize tissues and hydrate to water. If necessary, block for endogenous peroxidase and wash in DI water.2. Dilute concentrated Diva Decloaker at a ratio of 1:10 (1 ml Diva to 9 ml of deionized water).3. Place slides into 1X retrieval solution in a slide container (e.g. Coplin Jar, Tissue -Tek™ staining dish or metal slide canister).4. Retrieve sections under pressure using Biocare's Decloaking Chamber. Follow the recommendations on the antibody data sheet and Decloaking Chamber User Manual.5. Check solution for appropriate color change. (See Technical Note #1)6. Gently rinse by gradually adding DI water to the solution, then remove slides and rinse with DI water.Technical Notes:1. Concentrated Diva Decloaker is a bright yellow color. RTU or 1X solution is a pale yellow color. When the solution reaches 80-125°C, the solution turns yellow and indicates that the high temperature solution is at correct pH. Should the pH rise above 7.0, the solution turns a fuschia red color. Should the pH drop too low, thesolution turns a pink color.2. If using Biocare’s Desert Chamber Pro (a programmable turbo-action drying oven), dry sections at 25ºC overnight or at 37ºC for 30-60 minutes and then dry slides at 60ºC for 30 minutes.3. Use positive char ged slides (use Biocare’s Kling-On HIER Slides) and cut tissues at 4-5 microns. Do not use any adhesives in the water bath. Poor fixation and processing of tissues will cause tissue sections to fall off the slides, especially fatty tissues such as breast. Tissues should be fixed a minimum of 6-12 hours.4. Protocol time and temperatures for HIER can vary depending on the Decloaking Chamber model used. Please refer to the relevant Decloaking Chamber manual for appropriate protocol times and temperatures.Limitations:The protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, asresults may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.Catalog Number: DV2004 LX, MX Description: 100, 500 ml, concentrateQuality Control:Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (). 2011 Precautions:1. This product is not classified as hazardous. The preservative used in this reagent is Proclin 300 and the concentration is less than 0.25%. Overexposure to Proclin 300 can cause skin and eye irritation and irritation to mucous membranes and upper respiratory tract. The concentration of Proclin 300 in this product does not meet the OSHA criteria for a hazardous substance. Wear disposable gloves when handling reagents.2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water.3. Microbial contamination of reagents may result in an increase in nonspecific staining.4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.5. Do not use reagent after the expiration date printed on the vial.6. The SDS is available upon request and is located at /.7. Consult OSHA, federal, state or local regulations for disposal of any toxic substances. Proclin is a trademark of Rohm and Haas Company, or of its subsidiaries or affiliates.Troubleshooting:Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.。
动物硬组织线粒体粗提分离试剂盒产品说明书中文版主要
动物硬组织线粒体粗提分离试剂盒产品说明书（中文版）主要用途动物硬组织线粒体粗提分离试剂是一种旨在从动物硬组织中分离出完整而纯化的线粒体细胞器的权威而经典的技术方法。
该技术由大师级科学家精心研制、成功实验证明的。
适合于各种动物硬组织（心脏或肌肉）的线粒体的制备。
可以被用于细胞凋亡、信号传递、能量代谢、蛋白组学和病理生理学等的研究。
产品不含污染性蛋白酶和核酶，即到即用，性能稳定，分离产量和纯度堪称同类产品最佳。
技术背景线粒体细胞器的分离是现代细胞生物学研究的最常用的手段之一。
从任何组织或细胞分离线粒体的技术方法基本上采用：第一，通过机械或化学方法破裂细胞；第二，通过低速差速离心去除残渣碎屑和巨大细胞器；第三，通过高速差速离心获得线粒体；甚至，第四，可以通过等密度离心获得纯度更高的线粒体。
产品内容清理液（Reagent A）毫升裂解液（Reagent B）毫升净化液（Reagent C）毫升强化液（Reagent D）毫升保存液（Reagent E）毫升酶解液（Reagent F）毫升产品说明书 1份保存方式保存净化液（Reagent C）和酶解液（Reagent F）在－20℃冰箱里，其余的保存在4℃冰箱里，有效保证12月用户自备15毫升锥形离心管：用于线粒体初步制备操作的容器1.5毫升离心管：用于保存线粒体的容器4℃台式离心机：用于沉淀细胞4℃超速离心机：用于分离细胞器成分DOUNCE匀浆器：用于裂解细胞实验步骤一、 组织匀浆法实验开始前，将试剂盒里的净化液（Reagent C）冻融，然后移出xx毫升净化液（Reagent C）和xx毫升的裂解液（Reagent B）到15毫升锥形离心管里，混匀后，标记为裂解工作液，放进冰槽里备用。
然后进行下列操作。
1．手术取出动物组织，并秤重以确定1克组织重量（注意：实验前最好使动物空腹12至24小时）2．（选择步骤）放进预冷的15毫升锥形离心管3．（选择步骤）加入xx毫升清理液（Reagent A）4．（选择步骤）小心抽去清理液（Reagent A）5．即刻用刀片切碎组织6．放进一个预冷的15毫升锥形离心管7．加入预冷的xx毫升酶解液（Reagent F），充分混匀8．放进冰槽里孵育3分钟9．放进4℃台式离心机离心2分钟，速度为1000g10．小心抽去上清液11．加入预冷的xx毫升清理液（Reagent A）和xx毫升净化液（Reagent C），充分混匀12．放进4℃台式离心机离心2分钟，速度为1000g13．小心抽去上清液14．加入预冷的xx毫升裂解工作液15．涡旋震荡5秒，充分混匀16．即刻放入预冷的DOUNCE匀浆器17．在冰槽里用研磨棒匀化组织（约80下）（注意：参见注意事项7）18．将所有组织匀浆物移入预冷的15毫升锥形离心管19．放进4℃台式离心机离心10分钟，速度为1500g20．小心移出上清液到另一个新的预冷的15毫升锥形离心管——此步骤去除细胞核和未溶解的细胞21．放入4℃超速离心机离心10分钟，速度为10000g22．小心抽去上清液，保留沉淀颗粒——此步骤获得线粒体沉淀物（注意：如果进行线粒体DNA萃取，直接进入线粒体DNA萃取试剂盒的步骤4，继续下去）23．（选择步骤）加入预冷的xx毫升保存液（Reagent E）24．（选择步骤）放进4℃超速离心机再次离心5分钟，速度为10000g25．（选择步骤）小心抽去上清液26．加入xx毫升保存液（Reagent E），充分混匀27．即刻移入1.5毫升离心管，放进－70℃冰箱里保存二、 化学处理法实验开始前，将试剂盒里的净化液（Reagent C）冻融，然后移出xx毫升净化液（Reagent C）和xx毫升的裂解液（Reagent B）到15毫升锥形离心管里，混匀后，标记为裂解工作液，放进冰槽里备用。
霉酚酸测定试剂盒(荧光免疫层析法)产品技术要求danda
霉酚酸测定试剂盒(荧光免疫层析法)组成：适用范围：该产品用于体外定量检测人血清、血浆或全血中的霉酚酸含量。
1.1规格1人份/盒；10人份/盒；25人份/盒；50人份/盒；100人份/盒质控品(选配,2水平) ：0.5mL×2； 1mL×21.2组成试剂盒组成见表1表1霉酚酸测定试剂盒组成注：质控品赋值具有批特异性，每批次靶值详见标签。
2.1 外观试剂盒外观应整洁, 文字符号标识清晰，液体无渗漏，测试卡完整无破损，质控品为冻干疏松体，复溶后为无色至淡黄色液体。
2.2空白限应不高于0.1μg/mL。
2.3线性范围在[0.1，20] μg/mL内，相关系数R应不小于0.990。
2.4重复性重复测试（2.5±0.5）μg/mL和（10±2）μg/mL的样本，所得结果的变异系数（CV%）应不大于15%。
2.5批间差测试（2.5±0.5）μg/mL和（10±2）μg/mL的样本，批间相对极差（R）应不大于15%。
2.6准确度回收率为85～115％。
2.7质控品2.7.1质控品赋值有效性试剂盒内的质控品，检测结果均在质控范围内。
2.7.2质控品瓶间差瓶间差CV应不大于15%。
2.7.3复溶稳定性质控品复溶后在2～8℃密封避光保存24h。
检测复溶后的质控品，检测结果均在质控范围内。
2.8 效期稳定性试剂有效期为18个月。
取到效期后3个月内试剂盒进行检测，测定结果应符合2.2、2.3、2.4、2.6、2.7项要求。
2.9溯源性根据GB/T21415-2008的要求，校准曲线溯源至工作校准品，工作校准品可溯源至国家药品标准物质10759。
TMA-DPH-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-25-2019Print Date:Mar.-25-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :TMA-DPHCatalog No. :HY-D0986CAS No. :115534-33-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C28H31NO3SMolecular Weight:461.62CAS No. :115534-33-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: -20°C, protect from lightShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
安捷伦产品目录
15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤 優秀的溫控設備讓各個 well 都能保持溫度的穩定 七吋的高解析度觸控螢幕讓操作上更為簡便 可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題
常用化学试剂标识
常用化学试剂标识序号略写中文英文1 ar 分析纯 analytical reagent2 bc 生化试剂 biochemical3 bp 英国药典 british pharmacopoeia4 br 生物试剂 biological reagent5 bs 生物染色剂 biological stain6 cp 化学纯 chemical pure7 ep 特纯 extra pure8 fcm 络合滴定用 for complexometry9 fcp 层析用 for chromatography purpose10 fmp 显微镜用 for microscopic purpose11 fs 合成用 for synthesis12 gc 气相色谱 gas chromatography13 gr 优级纯 guaranteed reagent14 hplc 高压液相色谱 high preussuer liquid chromatography15 ind 指示剂 indicator16 lr 实验试剂 laboratoryreagent17 osa 有机分析标准 organic analyfical standard18 pa 分析用 pro analysis19 pract 实习用 practical use20 pt 基准试剂 primary reagent21 pur 纯 pure purum22 puriss 特纯 purissmum23 sp 光谱纯 spectrum pure24 tech 工业用 techincal grade25 tlc 薄层色谱 thin layer chromatography26 uv 分光纯（光学纯、紫析分光光度纯） ultra violet pure实验试剂：缩写为lr，又称四级试剂。
化学纯试剂：缩写为cp，又称三级试剂，一般瓶上用深蓝色标签。
分析纯试剂：缩写为ar，又称二级试剂，一般瓶上用红色标签。
MedDRA
MedDRA®术语选择：考虑要点ICH 认可的 MedDRA 用户指南2022年3月目录SECTION 1 –引言 (1)1.1 本文档的目的 (1)1.2 使用 MedDRA (1)1.3 如何使用本文档 (2)1.4 首选方案 (2)1.5 MedDRA 浏览工具 (2)SECTION 2 –术语选择一般原则 (3)2.1 源数据的质量 (3)2.2 质量保证 (3)2.3 不要改动 MedDRA (3)2.4 始终选择低位语 (3)2.5 只选择现行低位语 (5)2.6 何时就术语提出申请 (5)2.7 选择术语时采用医学判断 (5)2.8 选择多个术语 (5)2.9 查看层级结构 (6)2.10 编码所有报告信息，但不要添加信息 (6)SECTION 3 –术语选择要点 (7)3.1 在有或没有报告体征和症状情况下的确定诊断和临时诊断 (7)3.2 死亡和其他患者转归 (10)3.2.1 死亡且报告了 AR/AE (10)3.2.2 报告信息里只有死亡 (11)3.2.3 提供重要临床信息的死亡术语 (11)3.2.4 其他患者转归（非致命） (11)3.3 自杀和自我伤害 (12)3.3.1 报告了用药过量 (12)3.3.2 报告了自我伤害 (12)3.3.3 实施自杀行为致死 (12)3.4 矛盾/有歧义/含糊的信息 (13)3.4.1 矛盾的信息 (13)3.4.2 有歧义的信息 (13)3.4.3 含糊的信息 (13)3.5 组合术语 (14)3.5.1 诊断和体征/症状 (14)3.5.2 一个状况比另一个更具体 (14)3.5.3 可以找到 MedDRA 组合术语 (15)3.5.4 何时“拆分”成多个 MedDRA 术语 (15)3.5.5 事件伴随原有状况 (16)3.6 年龄与事件 (16)3.6.1 MedDRA 术语能同时包含年龄和事件 (16)3.6.2 MedDRA 术语不能同时包含年龄和事件 (16)3.7 身体部位与事件 (17)3.7.1 MedDRA 术语能同时包含身体部位和事件 (17)3.7.2 MedDRA 术语不能同时包含身体部位和事件 (17)3.7.3 发生在多处身体部位的事件 (18)3.8 具体部位与具体微生物感染 (18)3.8.1 MedDRA 术语能同时包含微生物和解剖学部位 (18)3.8.2 MedDRA 术语不能同时包含微生物和解剖学部位 (18)3.9 原有状况发生变化 (19)3.10 妊娠和哺乳期暴露 (20)3.10.1 事件发生在母亲身上 (20)3.10.2 事件发生在儿童或者胎儿身上 (20)3.11 先天性术语 (21)3.11.1 先天性状况 (21)3.11.2 获得性状况（出生时不存在） (21)3.11.3 不能明确是先天性还是获得性的状况 (22)3.12 肿瘤 (22)3.12.1 不推断恶性 (23)3.13 医疗和手术操作 (23)3.13.1 仅报告了操作 (23)3.13.2 同时报告了操作和诊断 (24)3.14 各类检查 (24)3.14.1 检查结果作为 AR/AE (24)3.14.2 检查结果与诊断一致 (25)3.14.3 检查结果与诊断不相关 (25)3.14.4 一组检查结果术语 (25)3.14.5 不带限定词的检查结果 (26)3.15 用药错误、意外暴露和职业暴露 (26)3.15.1 用药错误 (26)3.15.2 意外暴露和职业暴露 (31)3.16 误用、滥用和成瘾 (32)3.16.1 误用 (32)3.16.2 滥用 (32)3.16.3 成瘾 (33)3.16.4 药物流弊 (33)3.17 感染性病原体通过产品传播 (34)3.18 用药过量、毒性和中毒 (34)3.18.1 用药过量有临床后果 (35)3.18.2 用药过量没有临床后果 (35)3.19 器械相关术语 (36)3.19.1 器械相关事件有临床后果 (36)3.19.2 器械相关事件没有临床后果 (36)3.20 药物相互作用 (37)3.20.1 报告明确指出是相互作用 (37)3.20.2 报告没有明确指出是相互作用 (37)3.21 无不良作用和“正常”术语 (38)3.21.1 无不良作用 (38)3.21.2 “正常”术语的使用 (38)3.22 意外治疗效果 (38)3.23 治疗效果的改变 (38)3.23.1 缺乏治疗效果 (38)3.23.2 不推断缺乏治疗效果 (39)3.23.3 治疗效果增强、减弱、延长 (39)3.24 社会环境 (39)3.24.1 该 SOC 中术语的使用 (39)3.24.2 犯罪或虐待的非法行为 (40)3.25 病史和社会史 (41)3.26 产品使用的适应症 (41)3.26.1 医学状况 (42)3.26.2 复杂适应症 (42)3.26.3 带基因标记物或者异常病变的适应症 (43)3.26.4 防治与预防 (43)3.26.5 操作和诊断性检查作为适应症 (44)3.26.6 补充和替代治疗 (44)3.26.7 未报告适应症 (44)3.27 超说明书使用 (45)3.27.1 超说明书使用报告为适应症 (45)3.27.2 超说明书使用同时报告了 AR/AE (45)3.28 产品质量问题 (46)3.28.1 产品质量问题有临床后果 (46)3.28.2 产品质量问题没有临床后果 (47)3.28.3 产品质量问题与用药错误 (47)SECTION 4 –附录 (49)4.1 版本更新 (49)4.1.1 版本更新方法 (49)4.1.2 新版本采用时间 (50)4.2 链接及参考文献 (50)SECTION 1 –引言《监管活动医学词典》（MedDRA）术语集的设计旨在共享人用医疗产品的法规监管信息。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Data Sheet
BRD4 degrader AT1
பைடு நூலகம்
Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:
degrader AT1 (1-3 μM) causes remarkable Brd4-selective depletion and has no or little activity against Brd2 and Brd3 [1].
REFERENCES
1
[1]. Gadd MS, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 May;13(5):514-521.
Caution: Product has not been fully validated for medical applications. For research use only.
HY-111433 2098836-45-2 C₄₈H₅₈ClN₉O₅S₃ 972.68 Epigenetic Reader Domain; PROTAC Epigenetics; PROTAC Please store the product under the recommended conditions in the COA.
Solvent & Solubility
In Vitro
10 mM in DMSO
Preparing Stock Solutions
Mass Solvent Concentration 1 mM
5 mM
1 mg 1.0281 mL 0.2056 mL
10 mM
0.1028 mL
Please refer to the solubility information to select the appropriate solvent.
In Vitro
BRD4 degrader AT1 is a highly selective Brd4 degrader, with a Kd of 44 nM, for Brd4BD2 in cells. BRD4 degrader AT1 also shows Kds of 38.8 nM for a mutant Brd4BD2 (QVK), 111 ± 14 nM for Brd2BD1, 94 ± 9 nM for Brd2BD2, 35 ± 3 nM for Brd3BD1, 39 ± 8 nM for Brd3BD2, 75 ± 23 nM for Brd4BD1 and 35 ± 4 nM for a Brd2BD1 mutant (KEA). BRD4
Tel: 609-228-6898
Fax: 609-228-5909
E-mail: tech@
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
2
5 mg
5.1404 mL 1.0281 mL 0.5140 mL
10 mg
10.2809 mL 2.0562 mL 1.0281 mL
BIOLOGICAL ACTIVITY
Description
BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4 BD2 in cells.
IC₅₀ & Target
Kd: 44 nM (Brd4BD2, cell assay), 38.8 nM (Brd4BD2 QVK, cell assay), 111 nM (Brd2BD1, cell assay), 94 nM (Brd2BD2, cell assay), 35 nM (Brd3BD1, cell assay), 39 nM (Brd3BD2, cell assay), 75 nM (Brd4BD1, cell assay), 35 nM (Brd2BD1 KEA, cell assay)[1]